Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study von Mato, Anthony R, Shah, Nirav N, Jurczak, Wojciech, Cheah, Chan Y, Pagel, John M, Woyach, Jennifer A, Fakhri, Bita, Eyre, Toby A, Lamanna, Nicole, Patel, Manish R, Alencar, Alvaro, Lech-Maranda, Ewa, Wierda, William G, Coombs, Catherine C, Gerson, James N, Ghia, Paolo, Le Gouill, Steven, Lewis, David John, Sundaram, Suchitra, Cohen, Jonathon B, Flinn, Ian W, Tam, Constantine S, Barve, Minal A, Kuss, Bryone, Taylor, Justin, Abdel-Wahab, Omar, Schuster, Stephen J, Palomba, M Lia, Lewis, Katharine L, Roeker, Lindsey E, Davids, Matthew S, Tan, Xuan Ni, Fenske, Timothy S, Wallin, Johan, Tsai, Donald E, Ku, Nora C, Zhu, Edward, Chen, Jessica, Yin, Ming, Nair, Binoj, Ebata, Kevin, Marella, Narasimha, Brown, Jennifer R, Wang, Michael

Volltext

Current and emerging treatment options in primary mediastinal B-cell lymphoma von Fakhri, Bita, Ai, Weiyun

Volltext

Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER‐Medicare database von Fakhri, Bita, Fiala, Mark A., Shah, Nina, Vij, Ravi, Wildes, Tanya M.

Volltext

The role of acalabrutinib in adults with chronic lymphocytic leukemia von Fakhri, Bita, Andreadis, Charalambos

Volltext

Current and emerging treatment options for mantle cell lymphoma von Fakhri, Bita, Kahl, Brad

Volltext

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial von Shah, Nirav N, Wang, Michael, Roeker, Lindsey E, Patel, Krish, Woyach, Jennifer A, Wierda, William G, Ujjani, Chaitra S, Eyre, Toby A, Zinzani, Pier Luigi, Alencar, Alvaro J, Ghia, Paolo, Lamanna, Nicole, Hoffmann, Marc S, Patel, Manish R, Flinn, Ian, Gerson, James N, Ma, Shuo, Coombs, Catherine C, Cheah, Chan Y, Lech-Maranda, Ewa, Fakhri, Bita, Kim, Won Seog, Barve, Minal A, Cohen, Jonathon B, Jurczak, Wojciech, Munir, Talha, Thompson, Meghan C, Tsai, Donald E, Bao, Katherine, Cangemi, Nicholas A, Kherani, Jennifer F, Walgren, Richard A, Han, Hongmei, Ruppert, Amy S, Brown, Jennifer R

Volltext

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax von Thompson, Meghan C., Roeker, Lindsey E., Coombs, Catherine C., Jensen, Jeffrey L., Kamdar, Manali, Skarbnik, Alan, Pagel, John M., Bailey, Neil, Pu, Jeffrey J., Jacobs, Ryan, Hill, Brian T., Brander, Danielle M., Shadman, Mazyar, Ujjani, Chaitra S., Battiato, Kristen E., Komari, Celina J., Sacchi De Camargo Correia, Guilherme, Aronson, Julia H., Rhodes, Joanna M, Ghione, Paola, Fakhri, Bita, Barr, Paul M., Portell, Craig A., Lamanna, Nicole, Pinilla-Ibarz, Javier, Zelenetz, Andrew D., Schuster, Stephen J, Allan, John N., Eyre, Toby A., Mato, Anthony R.

Volltext

SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia von Fakhri, Bita, Danilov, Alexey

Volltext

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy von Lamanna, Nicole, Tam, Constantine S., Woyach, Jennifer A., Alencar, Alvaro J., Palomba, M. Lia, Zinzani, Pier Luigi, Flinn, Ian W., Fakhri, Bita, Cohen, Jonathon B., Kontos, Arrin, Konig, Heiko, Ruppert, Amy S., Chatterjee, Anindya, Sizelove, Richard, Compte, Livia, Tsai, Donald E., Jurczak, Wojciech

Volltext

CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL von Fakhri, Bita, Andreadis, Charalambos

Volltext

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN... von Scarfò, Lydia, Patel, Manish R., Eyre, Toby A., Jurczak, Wojciech, Lewis, David, Gastinne, Thomas, MA, Shuo, Cohen, Jonathon B., Patel, Krish, Brown, Jennifer R., Munir, Talha, Lech‐Maranda, Ewa, Hoffmann, Marc S., Ujjani, Chaitra S., Fakhri, Bita, Wang, Michael, Izutsu, Koji, Nagai, Hirokazu, Tam, Constantine S., Seymour, John F., Rhodes, Joanna, Vose, Julie, Mckinney, Matthew, Gerson, James N., Barve, Minal A., Kuss, Bryone, Koh, Youngil, Gao, Wei, Ruppert, Amy S., Walgren, Richard A., Tsai, Donald E., Nair, Binoj, Bao, Katherine, Mato, Anthony R., Cheah, Chan Y., Lia Palomba, M

Volltext

Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML von Westervelt, Peter, Slade, Michael, Fiala, Mark, Fakhri, Bita, Ghobadi, Armin

Volltext

Clonal Evolution in Multiple Myeloma von Fakhri, Bita, Vij, Ravi

Volltext

Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort von Cheung, Edna, Schumann, Claire, Zhang, Tian Y., Fakhri, Bita, Gotlib, Jason, Liedtke, Michaela, Shomali, William, Mannis, Gabriel

Volltext

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era von St. Martin, Emma C, Schwede, Matthew, Fakhri, Bita, Gotlib, Jason, Liedtke, Michaela, Shomali, William, Zhang, Tian Y., Mannis, Gabriel

Volltext

Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia von Ghosh, Nilanjan, Manzoor, Beenish S., Fakhri, Bita, Emechebe, Nnadozie, Alhasani, Hasan, Skarbnik, Alan, Jawaid, Dureshahwar, Shadman, Mazyar

Volltext

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia von Mato, Anthony R., Woyach, Jennifer A., Brown, Jennifer R., Ghia, Paolo, Patel, Krish, Eyre, Toby A., Munir, Talha, Lech-Maranda, Ewa, Lamanna, Nicole, Tam, Constantine S., Shah, Nirav N., Coombs, Catherine C., Ujjani, Chaitra S., Fakhri, Bita, Cheah, Chan Y., Patel, Manish R., Alencar, Alvaro J., Cohen, Jonathon B., Gerson, James N., Flinn, Ian W., Ma, Shuo, Jagadeesh, Deepa, Rhodes, Joanna M., Hernandez-Ilizaliturri, Francisco, Zinzani, Pier L., Seymour, John F., Balbas, Minna, Nair, Binoj, Abada, Paolo, Wang, Chunxiao, Ruppert, Amy S., Wang, Denise, Tsai, Donald E., Wierda, William G., Jurczak, Wojciech

Volltext

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study von Siddiqi, Tanya, Maloney, David G, Kenderian, Saad S, Brander, Danielle M, Dorritie, Kathleen, Soumerai, Jacob, Riedell, Peter A, Shah, Nirav N, Nath, Rajneesh, Fakhri, Bita, Stephens, Deborah M, Ma, Shuo, Feldman, Tatyana, Solomon, Scott R, Schuster, Stephen J, Perna, Serena K, Tuazon, Sherilyn A, Ou, San-San, Papp, Eniko, Peiser, Leanne, Chen, Yizhe, Wierda, William G

Volltext

Severe GI Toxicities Remain a Significant Source of Clinical Meaningful Morbidity Especially in Older Patients Receiving Autologous Transplant for Lymphoma von Shouse, Geoffrey, Frank, Annabel Kate, Aggarwal, Sanjay K., Kavalerchik, Edward, Frazer, John K, Finnegan, Paul, Fakhri, Bita

Volltext

Evaluation of Pulmonary Toxicities in Lymphoma Patients Receiving Brentuximab Vedotin von Guan, Tiffany, Lo, Mimi, Young, Rebecca, Boulbol, Fouad, Mouanoutoua, Hanson, Chu, Raymond, Ai, Weiyun Z., Abdulhaq, Haifaa, Fakhri, Bita

Volltext